Cat. No. | Product name | CAS No. |
DC23099 |
MK-2048
MK-2048 is a potent inhibitor of HIV-1 integrase (IN) and IN mutant R263K with IC50 of 2.6 nM and 1.5 nM, respectively. |
869901-69-9 |
DC9607 |
MK-2894
MK-2894 is a highly potent and selective second generation EP4 antagonist. |
1006036-87-8 |
DC24121 |
MK2-IN-1
MK2-IN-1 is a potent, selecitve, non-ATP competitive MAPKAPK2(MK2) inhibitor with IC50 of 0.11 uM. |
1314118-92-7 |
DC24120 |
MK2-IN-1 hydrochloride
Featured
MK2-IN-1 is a potent, selecitve, non-ATP competitive MAPKAPK2(MK2) inhibitor with IC50 of 0.11 uM. |
1314118-94-9 |
DC9397 |
MK-3207 (Hydrochloride)
MK-3207 is a potent and orally bioavailable CGRP receptor antagonist (IC50= 0.12 nM; Ki value= 0.024 nM); highly selective versus human AM1, AM2, CTR, and AMY3. |
957116-20-0 |
DC21297 |
MK-3281
MK-3281 is a potent and orally bioavailable inhibitor of HCV NS5B polymerase with IC50 of 6 nM. |
886041-60-7 |
DC7646 |
MK3697
MK-3697 is a third insomnia drug, currently being developed by Merck. MK-3697 is a potent and selective Orexin receptor antagonist with Ki = 0.95 nM. |
1224846-01-8 |
DC22731 |
MK-3901
MK-3901 is a potent, selective, orally active P2X3 antagonist with IC50 of 21 nM. |
1149750-69-5 |
DC20454 |
MK-4074 sodium salt
MK-4074 is a potent, liver-specific, orally active inhibitor of acetyl-CoA carboxylase ACC1 and ACC2 with IC50 of ~3 nM. |
1039758-18-3 |
DC21286 |
MK-4074
MK-4074 is a potent, liver-specific, orally active inhibitor of acetyl-CoA carboxylase ACC1 and ACC2 with IC50 of ~3 nM. |
1039758-22-9 |
DC9448 |
MK591
MK591(Quiflapon sodium) is a selective and specific 5-Lipoxygenase-activating protein (FLAP) inhibitor. |
147030-01-1 |
DC21299 |
MK-6169
MK-6169 is a potent, pan-genotype HCV NS5A inhibitor with replicon EC90 of 1-33 nM, retains potency against common resistance-associated substitutions in the major genotypes. |
1620479-63-1 |
DC20014 |
MK-6240
Featured
MK-6240 is a positron emission tomography (PET) tracer for neurofibrillary tangles (NFTs), exhibiting high specificity and selectivity for binding to NFTs. |
1841078-87-2 |
DC9455 |
MK-6892
MK-6892 is a highly potential GPR109A agonist with Ki value of 4.0 nM. |
917910-45-3 |
DC23121 |
MK-8033
MK-8033 is a potent, specific, dual c-Met/Ron kinases inhibitor with IC50 of 1/7 nM, also potently inhibits oncogenic c-Met activation loop mutants Y1230C, Y1230H and Y1235D with IC50 of 0.6-1.2 nM. |
1001917-37-8 |
DC23120 |
MK-8033 hydrochloride
MK-8033 is a potent, specific, dual c-Met/Ron kinases inhibitor with IC50 of 1/7 nM, also potently inhibits oncogenic c-Met activation loop mutants Y1230C, Y1230H and Y1235D with IC50 of 0.6-1.2 nM. |
1283000-43-0 |
DC20638 |
MK-8141
MK-8141 (ACT-077825) is a novel potent, selective, direct Renin inhibitor for the treatment of cardiovascular disorders.. |
903579-36-2 |
DC23176 |
MK-8245 trifluoroacetate
MK-8245 trifluoroacetate is a potent, selective liver-targeted stearoyl-CoA desaturase (SCD) inhibitor with IC50 of 3, 3 and 1 nM for rat, mouse and human SCD1 enzyme, respectively. |
1415559-41-9 |
DC23345 |
MK-8267
MK-8267 (SCH 2047069) is a potent, orally bioavailable, brain penetrant kinesin spindle protein (KSP) inhibitor with EC50 of 3 nM. |
1146209-50-8 |
DC21300 |
MK-8282
MK-8282 is a potent, selective, oral GPR119 agonist with EC50 of 10 and 58 nM for hGPR119 and mGPR119, respectively. |
|
DC11142 |
MK-8318
MK-8318 (MK8318) is a potent, selective, orally available CRTh2 receptor antagonist with Ki of 5 nM, shows nM potency in functional assay (cAMP IC50=8 nM, β-Arrestin IC50=3.5 nM. |
1416581-40-2 |
DC21301 |
MK-8325
MK-8325 is a potent, selective pan-genotype HCV NS5A inhibitor with IC50 of 15, 1 and 3 pM for GT1a, GT1b and GT2a, respectively. |
1334312-52-5 |